Does Blurred Vision from Wegovy Go Away?

What the clinical record actually shows about semaglutide and the eyes

The STEP 1 trial (the pivotal 68-week study of semaglutide 2.4mg published in the New England Journal of Medicine) was large enough to capture meaningful safety signals, and vision-related adverse events were documented in the trial programme, though they were not among the most frequently reported effects. The NHS medicines page for semaglutide lists blurred vision under side effects that affect fewer than one in ten people, placing it in the uncommon rather than common category. Prescribers working through the broader semaglutide clinical data understand two distinct mechanisms that can produce visual symptoms: a transient, glucose-related blurring that tends to settle quickly, and retinal complications associated with faster glucose lowering in people who already have diabetic eye disease. These are clinically different problems with different trajectories, and it matters which one a patient is experiencing.

The glucose-shift mechanism is straightforward. When semaglutide slows gastric emptying and reduces appetite, post-meal glucose excursions flatten out. In people whose eyes have adapted to chronically higher glucose levels, that correction can temporarily change the refractive state of the lens, producing mild blurring. This is the same phenomenon sometimes seen at the start of insulin therapy in people with type 2 diabetes, and it typically resolves as the body recalibrates. If you have been wondering whether semaglutide can cause blurry vision and what drives it, most people reporting short-lived soft-focus vision in the first week or two of treatment are likely experiencing this refractive shift, and it passes without intervention.

The retinopathy concern is different in character. People with pre-existing diabetic retinopathy who achieve rapid glucose lowering face a known risk of short-term worsening, a phenomenon observed across glucose-lowering therapies. If you have a diagnosis of diabetic eye disease, this is a conversation to have with your prescriber before treatment begins, not after symptoms appear. You can explore the broader picture of semaglutide and vision changes for a more detailed look at both mechanisms.

When blurred vision from Wegovy goes away on its own, and when it does not

The honest answer to the question this page is answering: transient, mild blurring that appears in the first week or two and is not getting worse generally does go away. Keeping a simple one-minute daily habit helps, each morning, cover one eye at a time and note whether your vision through each eye separately feels the same as the day before. Any asymmetry, any sudden change, any new floaters or flashes of light should bypass the watch-and-wait approach entirely.

Symptoms that warrant same-day medical attention include sudden vision loss in one or both eyes, a significant increase in blurring rather than a stable mild fogginess, new floaters, flashes, or a shadow or curtain across your visual field. These patterns are not consistent with the benign glucose-refractive mechanism and need proper assessment. The MHRA's Yellow Card scheme allows patients to report suspected side effects directly, a step worth taking if a vision change feels serious, so that regulators can track signals across the population using these medicines.

People using Wegovy who have not been diagnosed with diabetes are much less likely to experience the retinopathy-related worsening, because the mechanism requires pre-existing retinal disease. Their blurring, if it occurs at all, is more likely to be the lens-refractive variety, and it is more likely to resolve. Still, the rule is the same: if it is getting worse rather than better after two weeks, or if it is anything other than mild, see a clinician. Our dedicated page on Wegovy and vision changes covers how these symptoms tend to unfold across different patient profiles, which can help you judge whether what you are experiencing fits the expected pattern. You can also read more about how Wegovy can affect vision across different patient profiles.

How to manage the first weeks, and what your prescriber needs to know

Starting any GLP-1 medicine involves a period of adjustment. Nausea, fatigue and mild digestive changes are the most commonly discussed, but visual symptoms deserve the same practical attention. If you wear glasses or contact lenses and notice that your prescription feels slightly off in the first fortnight, it is worth mentioning to your optometrist before you book a retest, a temporary refractive shift does not mean you need new lenses, and an optometrist who knows you are on semaglutide can interpret your results accordingly.

Your prescriber should know about any eye conditions you have before treatment starts. This includes diabetic retinopathy at any stage, glaucoma, macular degeneration, or any recent changes in your prescription. The clinical review at the start of Wegovy treatment is exactly the place to raise these, at nume, every consultation is read by a GPhC-registered prescriber, not passed through automated scoring, so there is room for exactly this kind of relevant history. If you are already on treatment and have concerns about visual symptoms, the contact page connects you with the aftercare team seven days a week.

Wegovy sits within a wider GLP-1 landscape that is moving quickly. The Wegovy overview covers the full picture of what the medicine is licensed to do in the UK, and if you are weighing up whether it is the right option for your circumstances, a look at weight-loss treatment options more broadly is a sensible starting point. Cost context sits on a separate page in the allowlist, but for most people considering Wegovy, the clinical-suitability question comes well before the cost question, and that starts with a free consultation.

It is also worth noting that blurred vision is not the only psychological or sensory side effect people ask about. Questions about mood during treatment are common too; whether low mood from Wegovy resolves follows the same pattern of careful monitoring and prescriber contact if things do not settle.